The U.S. Food and Drug Administration today expanded the approved use
of Imbruvica (ibrutinib) for patients with Waldenström’s
macroglobulinemia (WM), a rare form of cancer that begins in the body’s
immune system. The drug received a breakthrough therapy designation for
this use.